Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age

NCT06855160 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06855160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06855160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3a, Open-Label, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of Intramuscular Administration of an Investigational Varicella Vaccine and Priorix Compared With Subcutaneous Administration of Varivax and Priorix, When Given as a First Dose to Healthy Children 12 to 15 Months of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Recruiting
Start date
April 17, 2025
Completion date
February 2, 2027
Enrollment
911 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

chickenpox